Amylyx Pharmaceuticals annual operating margin
2021
2022
2023
2024
Amylyx Pharmaceuticals's operating margin was −360.22% for fiscal 2024.
View full Amylyx Pharmaceuticals company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | −360.22% | −370.41 pp |
| 2023 | 2023-12-31 | 10.19% | +915.91 pp |
| 2022 | 2022-12-31 | −905.72% | +28107.62 pp |
| 2021 | 2021-12-31 | −29,013.33% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q3 2024 | 2024-09-30 | −18,187.74% | −18208.31 pp |
| Q1 2024 | 2024-03-31 | −137.78% | −134.90 pp |
| Q4 2023 | 2023-12-31 | 1.78% | +15851.35 pp |
| Q3 2023 | 2023-09-30 | 18.23% | +8059.63 pp |
| Q2 2023 | 2023-06-30 | 20.57% | — |
| Q1 2023 | 2023-03-31 | −2.87% | — |
| Q3 2022 | 2022-09-30 | −15,849.57% | — |
| Q3 2021 | 2021-09-30 | −8,041.40% | — |
Across the available reported history, Amylyx Pharmaceuticals's operating margin decreased from 10.19% to −360.22%, a change of −370.41 percentage points. The latest reported quarter, Q3 2024, shows −18,187.74%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Amylyx Pharmaceuticals filings at SEC.gov ↗